Related Experiment Video
Updated: Feb 7, 2026

Studying the Role of Alveolar Macrophages in Breast Cancer Metastasis
Published on: June 26, 2016
Role of immunotherapy in kidney cancer
Sebastiano Nazzani1,2, Amélie Bazinet1,3, Pierre I Karakiewicz1,3
1Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Québec, Canada.
Purpose Of Review:
To summarize current knowledge on promising immunotherapeutic agents and to provide a brief outline of current use of immunotherapeutic agents in patients with locally advanced or metastatic renal cell carcinoma (RCC).
Recent Findings:
Immunotherapy with mAbs directed against programed death cell protein 1, programed death-ligand 1 (PD-L1) and cytotoxic T-Lymphocyte Antigen 4 has become new first-line standard of care for moderate and poor-risk metastatic RCC patients. Similarly, the combination immune-oncology treatment and vascular endothelial growth factor (VEGF) mAbs also showed promising results in first-line therapy despite relative data immaturity. Finally, immune-oncology monotherapy (nivolumab) already represents second or third-line standard of care after tyrosine kinase inhibitor failure.
Summary:
Combination immune-oncology therapy represents the standard of care for management of intermediate-to-poor risk clear cell metastatic RCC. In addition, combination of immune-oncology and anti-VEGF antibody represents a treatment option across all risk levels in patient with elevated PD-L1 expression. Finally, nivolumab is one of two ideal treatment options in second-line clear cell metastatic RCC patients.
Insights
Immunotherapy, including immune-oncology treatments and vascular endothelial growth factor (VEGF) monoclonal antibodies (mAbs), is now standard care for advanced renal cell carcinoma (RCC). Nivolumab is a key option for second-line treatment after other therapies fail.
Area of Science:
- Oncology
- Immunotherapy
- Renal Cell Carcinoma Research
Background:
- Metastatic renal cell carcinoma (RCC) treatment has evolved significantly.
- Immunotherapy has emerged as a critical modality in managing advanced RCC.
Purpose of the Study:
- To review current knowledge on immunotherapeutic agents for advanced or metastatic RCC.
- To outline the current application of these agents in RCC patient care.
Main Methods:
- Review of current literature on immunotherapeutic agents in RCC.
- Analysis of clinical data for immune-oncology treatments and VEGF inhibitors.
Main Results:
- Immune-oncology agents targeting PD-1/PD-L1 and CTLA-4 are now first-line standards for moderate/poor-risk metastatic RCC.
- Combination therapies (immune-oncology plus VEGF mAbs) show promise in first-line settings.
- Immune-oncology monotherapy (nivolumab) is a standard second or third-line option post-tyrosine kinase inhibitor failure.
Conclusions:
- Combination immune-oncology therapy is the standard for intermediate-to-poor risk clear cell metastatic RCC.
- Immune-oncology plus anti-VEGF antibody therapy is an option for patients with high PD-L1 expression across risk levels.
- Nivolumab is a primary choice for second-line treatment in clear cell metastatic RCC.
Related Concept Videos
Tumor Immunotherapy
Kidney Structure
Role of Septins
Cellular Functions of Septins
Recent studies have revealed the multifaceted roles of septins in various cellular processes such as cytokinesis, ciliogenesis, and neurogenesis. Septins act as scaffolds and...
The Role of Culture
Role-Based Identity
Role of Hippocampus in Memory

